Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 21, 2026
TickeronGET DAILY SIGNALS
SBIO vs XBI: Weighing Two Biotech ETFs for Targeted Exposure

SBIO vs XBI: Weighing Two Biotech ETFs for Targeted Exposure

Key Takeaways

  • Different methodologies, same theme: SBIO is a market-cap-weighted, clinical-trial-stage filter, while XBI is an equal-weighted, broad biotechnology index.
  • Cost advantage: XBI carries a 0.35% expense ratio versus SBIO's 0.50%, a meaningful structural edge in a long-hold sector.
  • Diversification profile: XBI holds roughly 166 stocks versus SBIO's approximately 90, with no single position typically exceeding about 2–3% of assets.
  • Liquidity gap: XBI is a far larger and more actively traded fund, with assets under management (AUM) well above $10 billion versus SBIO's roughly $200 million.
  • Risk profile: SBIO concentrates in small- and mid-cap clinical-stage names, historically producing higher volatility than XBI's broader mix of large- and mid-cap biotech.
  • Tickeron AI Verdict: XBI is the favored ticker, reflecting lower cost, superior diversification, and stronger structural liquidity.

Introduction

Investors looking for biotechnology exposure often compare two distinct options: the ALPS Medical Breakthroughs ETF (SBIO) and the SPDR S&P Biotech ETF (XBI). Both are passive ETFs focused on U.S.-listed biotech and pharmaceutical companies, yet they follow quite different approaches. SBIO screens for clinical-stage companies in a smaller, market-cap-weighted universe, while XBI delivers equal-weighted coverage across a wider range of the sector. The choice comes down to aligning each fund’s construction with specific investment objectives.

ALPS Medical Breakthroughs ETF (SBIO) Overview

SBIO tracks the S-Network Medical Breakthroughs Index with a clinical focus. Holdings must have drug candidates in Phase II or Phase III FDA trials and market caps typically between $200 million and $5 billion. The fund holds about 90 stocks and weights them by market cap, so larger names within that group carry more influence. Recent top holdings have included CRNX, APGE, CGON, DNTH, and ORKA. Exposure is almost entirely in biotechnology and pharmaceuticals. The expense ratio stands at 0.50%, and the fund launched in December 2014. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

SPDR S&P Biotech ETF (XBI) Overview

XBI follows the S&P Biotechnology Select Industry Index on a modified equal-weighted basis. No single holding dominates, with each typically around 1–3% of assets. The fund includes roughly 166 stocks that range from large-cap established names to smaller developers. Representative holdings include MRNA, TWST, NTRA, ABBV, UTHR, AMGN, and BIIB. Sector allocation is nearly all biotechnology. XBI’s expense ratio is 0.35%, and it has traded since January 2006, which supports its deeper liquidity profile.

Industry and Thematic Backdrop

Both ETFs operate in a sector supported by long-term drivers such as demographic trends, ongoing M&A activity, and a pipeline of FDA approvals in areas like oncology and rare diseases. Interest-rate expectations matter because many clinical-stage firms rely on external capital and are valued on distant cash flows. Regulatory shifts, drug-pricing discussions, and patent expirations at larger pharma companies also shape sentiment. The main risk remains binary clinical-trial results that can drive sharp moves in individual holdings and, by extension, these concentrated funds.

Performance and Positioning Comparison

The two funds have tended to move in the same direction but with different amplitudes. SBIO’s emphasis on small- and mid-cap Phase II/III names often magnifies both gains and losses compared with XBI’s broader equal-weighted mix. XBI’s inclusion of large-cap names with recurring revenue, such as AMGN, BIIB, and GILD, adds a layer of earnings stability that SBIO does not have. In risk-on environments driven by deals or positive trial data, SBIO’s higher-beta stance can lead; in risk-off periods tied to higher rates or tighter financing, XBI’s diversification has historically helped moderate volatility. This difference in positioning remains central to the comparison.

Using Tickeron AI Tools for ETF Research

When comparing sector ETFs like these, I turn to Tickeron’s AI Screener to quickly filter holdings by market cap, volatility, and technical patterns. It helps surface how the two funds stack up against broader industry peers without manual screening. From what I see, this kind of tool adds efficiency when evaluating structural differences in cost, liquidity, and diversification.

Tickeron AI Verdict

Based on structural factors rather than recent price moves, the AI analysis points to XBI over SBIO at present. XBI offers the lower expense ratio, wider diversification across about 166 holdings, equal-weight construction that reduces concentration risk, and stronger liquidity. Although SBIO’s clinical-stage focus can produce stronger momentum in biotech rallies, its narrower scope and higher costs increase sensitivity to drawdowns. Overall, the advantages in cost efficiency, diversification, and liquidity make XBI the more resilient choice for broad biotechnology exposure.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: XBI, SBIO

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Momentum Indicator for XBI turns negative, indicating new downward trend

XBI saw its Momentum Indicator move below the 0 level on November 11, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In 82 of the 91 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for XBI turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 48 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

XBI moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for XBI crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for XBI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 295 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Notable companies

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the State Street SPDR S&P Biotech ETF (XBI) ETF is 15.28B. The market cap for tickers in the group ranges from 136.65M to 514.78B. ABBV holds the highest valuation in this group at 514.78B. The lowest valued company is CMPX at 136.65M.

High and low price notable news

The average weekly price growth across all stocks in the State Street SPDR S&P Biotech ETF (XBI) ETF was -7%. For the same ETF, the average monthly price growth was -8%, and the average quarterly price growth was 7%. SLS experienced the highest price growth at 74%, while SMMT experienced the biggest fall at -30%.

Volume

The average weekly volume growth across all stocks in the State Street SPDR S&P Biotech ETF (XBI) ETF was 26%. For the same stocks of the ETF, the average monthly volume growth was 17% and the average quarterly volume growth was -12%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 46
Price Growth Rating: 59
SMR Rating: 87
Profit Risk Rating: 80
Seasonality Score: 16 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.